Targeting breast 우리 카지노 with high HER2 expression, expected to be key in HER2-positive 우리 카지노 treatment
[by Yu, Suin] AbClon, a company specializing in antibody and cell therapy development, announced on March 26 that its self-developed gastric 우리 카지노 treatment candidate, ‘AC101 (Henlius’ development code: HLX22)’, is also under development as a treatment for breast 우리 카지노 with a high human epidermal growth factor receptor type 2 (HER2) expression rate.
우리 카지노 is an antibody treatment derived from AC101, with the technology transferred by Abclon to Henlius in 2016. According to Henlius’ business report, the substance is a key component of their pipeline, demonstrating superior efficacy compared to existing standard treatments.
HLX22 targets a specific part of the HER2 protein, offering more precise and efficient action on 우리 카지노 cells compared to existing treatments by differentiating the antigen-binding site of HER2. When combined with ‘trastuzumab (HLX02)’ targeting HER2, the HER2 protein on the surface of 우리 카지노 cells is more effectively removed, thereby inhibiting 우리 카지노 cell growth signals.
The ‘HLX22 and trastuzumab combination therapy’ demonstrated superior efficacy compared to the existing ‘trastuzumab + pertuzumab combination therapy’ in treating gastric 우리 카지노, with therapeutic benefits observed regardless of the PD-L1 expression level. In particular, the company highlighted that severe diarrhea, a common side effect in existing first-line HER2-positive gastric 우리 카지노 treatments, was not observed with HLX22, leading to a positive evaluation of its safety profile.
The current standard treatment for metastatic gastric 우리 카지노 and gastroesophageal junction 우리 카지노 is the ‘trastuzumab + chemotherapy combination therapy,’ approved in 2010. This therapy recorded a progression-free survival (PFS) of 6.7 months, an overall survival (OS) of 13.8 months, and a duration of response (DoR) of 6.9 months. In contrast, the company emphasized that the HLX22 combination therapy demonstrated superior clinical efficacy, with outcomes that exceeded the PFS, OS, and DoR observed in the standard treatment, based on a median follow-up period of 20.3 months.
Conversely, HLX22 is being developed as a treatment for breast 우리 카지노 with high HER2 expression, further expanding its potential scope of application. HER2-positive breast 우리 카지노 accounts for approximately 15-20% of all breast 우리 카지노s, with 2.3 million new cases diagnosed annually. This makes it a key market for HER2-targeted therapies, alongside gastric 우리 카지노. Given its diverse therapeutic potential, the company anticipates that HLX22 could establish a new standard for solid 우리 카지노 treatment.
“HLX22 has shown outstanding efficacy in treating gastric 우리 카지노 and shows promising potential for the treatment of other solid 우리 카지노s, such as breast 우리 카지노,” an AbClon official said. “It is expected to play a crucial role in targeting HER2-positive 우리 카지노s. HLX22 is poised to become an important treatment option in more 우리 카지노 treatment markets in the future.”
“HLX22’s innovative approach has the potential to transform the future paradigm of 우리 카지노 treatment by more precisely targeting and blocking the growth signals of 우리 카지노 cells,” the official further emphasized. “It can particularly offer hope to 우리 카지노 patients who have difficulty responding to existing treatments.”